Evaluation of the targeted delivery of 5-fluorouracil and ascorbic acid into the brain with ultrasound-responsive nanobubbles

Miura, Yusuke; Fuchigami, Yuki; Hagimori, Masayori; Sato, Hiroki; Ogawa, Kazuhiro; Munakata, Chie; Wada, Mitsuhiro; Maruyama, Kazuo; Kawakami, Shigeru

doi:10.1080/1061186x.2017.1419354

Cited by 9 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no beneficial effect on ischemia-reperfusion-induced oxidative stress was observed on lipid peroxidation over that of the non-encapsulated dose of vitC [72]. Regardless, this technology has shown some promise and continues to be explored in anticancer therapy, where chemotherapeutics can be delivered together with vitC for a potentially synergistic effect [73]. In another sophisticated approach, the particular ability of the brain to take up vitC has been used by linking ASC to the surface of liposomes containing chemotherapeutics thereby making a brain-specific drug delivery system by using the endogenous vitC transport mechanisms [74].…”

Section: Pharmacokinetics Of Vitamin Cmentioning

confidence: 99%

The Pharmacokinetics of Vitamin C

2019

View full text Add to dashboard Cite

The pharmacokinetics of vitamin C (vitC) is indeed complex. Regulated primarily by a family of saturable sodium dependent vitC transporters (SVCTs), the absorption and elimination are highly dose-dependent. Moreover, the tissue specific expression levels and subtypes of these SVCTs result in a compartmentalized distribution pattern with a diverse range of organ concentrations of vitC at homeostasis ranging from about 0.2 mM in the muscle and heart, and up to 10 mM in the brain and adrenal gland. The homeostasis of vitC is influenced by several factors, including genetic polymorphisms and environmental and lifestyle factors such as smoking and diet, as well as diseases. Going from physiological to pharmacological doses, vitC pharmacokinetics change from zero to first order, rendering the precise calculation of dosing regimens in, for example, cancer and sepsis treatment possible. Unfortunately, the complex pharmacokinetics of vitC has often been overlooked in the design of intervention studies, giving rise to misinterpretations and erroneous conclusions. The present review outlines the diverse aspects of vitC pharmacokinetics and examines how they affect vitC homeostasis under a variety of conditions.

show abstract

Section: Pharmacokinetics Of Vitamin Cmentioning

confidence: 99%

The Pharmacokinetics of Vitamin C

2019

View full text Add to dashboard Cite

show abstract

“…123) Seo et al prepared 64 Cu-labeled liposomes and micelles and evaluated their accumulation in brain tumors after intravenous administration to gliomabearing rats. 124) Those reports suggested that radioactive nanocarriers may be useful in the diagnosis of cerebral diseases.…”

Section: Systemic Imaging Methodsmentioning

confidence: 99%

Recent Strategies for Targeted Brain Drug Delivery

2020

Self Cite

View full text Add to dashboard Cite

Because the brain is the most important human organ, many brain disorders can cause severe symptoms. For example, glioma, one type of brain tumor, is progressive and lethal, while neurodegenerative diseases cause severe disability. Nevertheless, medical treatment for brain diseases remains unsatisfactory, and therefore innovative therapies are desired. However, the development of therapies to treat some cerebral diseases is difficult because the blood-brain barrier (BBB) or blood-brain tumor barrier prevents drugs from entering the brain. Hence, drug delivery system (DDS) strategies are required to deliver therapeutic agents to the brain. Recently, brain-targeted DDS have been developed, which increases the quality of therapy for cerebral disorders. This review gives an overview of recent brain-targeting DDS strategies. First, it describes strategies to cross the BBB. This includes BBB-crossing ligand modification or temporal BBB permeabilization. Strategies to avoid the BBB using local administration are also summarized. Intrabrain drug distribution is a crucial factor that directly determines the therapeutic effect, and thus it is important to evaluate drug distribution using optimal methods. We introduce some methods for evaluating drug distribution in the brain. Finally, applications of brain-targeted DDS for the treatment of brain tumors, Alzheimer's disease, Parkinson's disease, and stroke are explained.

show abstract